Granulocytapheresis in steroid-dependent and steroid-resistant patients with inflammatory bowel disease: A prospective observational study

Journal of Crohn's and Colitis

Volumn 7, Issue 12, 2013, Pages e692-e697

  Sacco, Rodolfo ^a   Romano, Antonio ^a   Mazzoni, Alessandro ^a   Bertini, Marco ^a   Federici, Graziana ^a   Metrangolo, Salvatore ^a   Parisi, Giuseppe ^a   Nencini, Cecilia ^a   Giampietro, Celeste ^a   Bertoni, Michele ^a   Tumino, Emanuele ^a   Scatena, Fabrizio ^a   Bresci, Giampaolo ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

Crohn's Disease; Granulocytapheresis; Steroid dependence; Steroid resistance; Ulcerative Colitis

Indexed keywords

MESALAZINE; METHYLPREDNISOLONE;

ADULT; APHERESIS; ARTICLE; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; FEMALE; FOLLOW UP; GRANULOCYTAPHERESIS; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REMISSION; TREATMENT DURATION; ULCERATIVE COLITIS;

CROHN'S DISEASE; GRANULOCYTAPHERESIS; STEROID-DEPENDENCE; STEROID-RESISTANCE; ULCERATIVE COLITIS;

ADULT; ANTI-INFLAMMATORY AGENTS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG RESISTANCE; FECES; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTES; HUMANS; LEUKAPHERESIS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX;

EID: 84887618133     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2013.06.012     Document Type: Article

References (30)

1. Faubion W.A., Loftus E.V., Harmsen W.S., Zinsmeister A.R., Sandborn W.J. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001, 121:255-526.
2. Fregan B.G. Editorial: 5ASA therapy for active Crohn's disease old friends, old data and new conclusion. Clin Gastroenterol Hepatol 2004, 2:376-378.
3. Munkholm P., Langholz E., Davidsen M., Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994, 35:360-362.
4. Triantafillidis J.K., Merikas E., Georgopoulos F. Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des Devel Ther 2011, 5:185-210.
5. Su C., Lichtenstein G.R. Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine. Gastroenterol Clin North Am 2004, 33:209-234.
6. Dignass A., Van Assche G., Lindsay J.O., Lémann J., Sooderholm J., Colombel J.F., et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010, 4:28-62.
7. Cottone M., Renna S., Orlando A., Mocciaro F. Medical management of Crohn's disease. Expert Opin Pharmacother 2011, 12:2505-2525.
8. Bresci G., Romano A., Mazzoni A., Scatena F., Altomare E., Capria A., et al. Feasibility and safety of granulocytapheresis in Crohn's disease: a prospective cohort study. Gastroenterol Clin Biol 2010, 34:682-686.
9. Bresci G., Parisi G., Bertoni M., Mazzoni A., Scatena F., Capria A. Treatment of active steroid-refractory inflammatory bowel diseases with granulocytapheresis: our experience with a prospective study. World J Gastroenterol 2006, 12:2201-2204.
10. Yamaji K., Fukunaga K., Yamane S., Sueoka A., Nose Y. Current therapeutic apheresis technologies for inflammatory bowel disease. Ther Apher 1998, 2:105-108.
11. Kawamura A., Saitoh M., Yonekawa M., Horie T., Ohizumi H., Tamaki T., et al. New technique of leukocytapheresis by the use of non-woven polyester fiber filter for inflammatory bowel disease. Ther Apher 1999, 3:334-337.
12. Kohgo Y., Ashida T., Maemoto A., Ayabe T. Leukocytapheresis for treatment of IBD. J Gastroenterol 2003, 380:51-54.
13. Sawada K., Muto T., Shimoyama T., Satomi M., Sawada T., Nagawa H., et al. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr Pharm Des 2003, 9:307-321.
14. Saniabadi A.R., Hanai H., Takeuchi K., Umemura K., Nakashima M., Adachi T., et al. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial 2003, 7:48-59.
15. Suzuki Y., Yoshimura N., Saniabadi A.R., Saito Y. Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naive patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci 2004, 49:565-571.
16. Yamamoto T., Umegae S., Matsumoto K. Long-term clinical impact of early introduction of granulocyte and monocyte adsorptive apheresis in new onset, moderately active, extensive ulcerative colitis. J Crohns Colitis 2012, 6:750-755.
17. Takayama T., Kanai T., Matsuoka K., Okamoto S., Sujino T., Mikami Y., et al. Long-term prognosis of patients with ulcerative colitis treated with cytapheresis therapy. J Crohns Colitis 2013, 7:e49-e54.
18. Best W.R., Becktel J.M., Singleton J.W., Kern F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976, 70:439-444.
19. Sandborn W.J., Feagan B.G., Hanauer S.B., Lochs H., Löfberg R., Modigliani R., et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002, 122:512-530.
20. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. Br Med J 1989, 298:82-86.
21. Passalacqua S., Ferraro P.M., Bresci G., D'Ovidio V., Astegiano M., Principi M., et al. The Italian Registry of Therapeutic Apheresis: granulocyte-monocyte apheresis in the treatment of inflammatory bowel disease. A multicentric study. J Clin Apher 2011, 26:332-337.
22. Sands B.E., Sandborn W.J., Wolf D.C., Katz S., Safdi M., Schwartz D.A., et al. Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease. J Clin Gastroenterol 2006, 40:482-489.
23. Sands B.E., Sandborn W.J., Feagan B., Löfberg R., Hibi T., Wang T., et al. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology 2008, 135:400-409.
24. D'Ovidio V., Meo D., Viscido A., Bresci G., Vernia P., Caprilli R. Predictive factors of clinical response in steroid-refractory ulcerative colitis treated with granulocyte-monocyte apheresis. World J Gastroenterol 2011, 17:1831-1835.
25. Naganuma M., Funakoshi S., Sakuraba A., Takagi H., Inoue N., Ogata H., et al. Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm Bowel Dis 2004, 10:251-257.
26. Domènech E., Hinojosa J., Esteve-Comas M., Gomollón F., Herrera J.M., Bastida G., et al. Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther 2004, 20:1347-1352.
27. Cabriada J.L., Ibargoyen N., Hernández A., Bernal A., Castiella A. Sustained remission after steroids and leukocytapheresis induced response in steroid-dependent ulcerative colitis: results at 1year. Dig Liver Dis 2010, 42:432-435.
28. Cabriada J.L., Domènech E., Ibargoyen N., Hernández V., Clofent J., Ginard D., et al. Leukocytapheresis for steroid-dependent ulcerative colitis in clinical practice: results of a nationwide Spanish registry. J Gastroenterol 2012, 47:359-365.
29. Dignass A.U., Eriksson A., Kilander A., Pukitis A., Rhodes J.M., Vavricka S. Clinical trial: five or ten cycles of granulocyte-monocyte apheresis show equivalent efficacy and safety in ulcerative colitis. Aliment Pharmacol Ther 2010, 31:1286-1295.
30. Silverman S.L. From randomized controlled trials to observational studies. Am J Med 2009, 122:114-120.